银酸和肠道微生物群:对健康个体的差异影响和刺激性肠道综合征亚型
Zhi Du1,2, Chengman Zhao3, Jiabin Li1,2
1Department of Pharmacy, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, Zhejiang, China.
PeerJ
|April 21, 2025
概括
在健康和易怒肠综合征与腹 (IBS-D) 模型中,金色化物改变了肠道微生物群的组成,丰富了像Stenotrophomonas这样的特定细菌. 这表明在IBS治疗中有针对性的微生物群治疗的潜力.
科学领域:
- 微生物组研究的研究.
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 刺激性肠综合征 (IBS) 是一种普遍存在的胃肠疾病,其机制尚不清楚.
- 肠道微生物群失调与IBS亚型有关.
- 银化物对IBS症状缓解有希望,但它们对IBS相关的肠道微生物群的影响还未得到充分研究.
研究的目的:
- 对健康个体和IBS-D或IBS-C患者的肠道微生物群的金氏化物影响进行研究.
- 通过微生物组调制来探索金氏酸的潜在治疗机制.
主要方法:
- 利用体外发酵模型模拟健康,IBS-D和IBS-C条件.
- 采用16S rRNA测序和生物信息学分析来评估微生物的组成和多样性.
- 应用LEfSe分析以识别差异丰富的种类.
主要成果:
- 在用金氏治疗和对照组之间没有观察到α或β多样性的显著变化.
- 在ginsenoside治疗后,发现了特定细菌属的显著丰富,包括健康模型中的Stenotrophomonas和Achromobacter,以及IBS-D模型中的Pseudomonas和Stenotrophomonas.
- 在健康和IBS-D模型中,鉴别出了对人参化物反应的明显微生物特征.
结论:
- 在健康和IBS-D模型中,丁化物治疗会诱导肠道微生物群组成的特定变化.
- 这些发现支持人参化物在调节肠道微生物群的胃肠道健康方面的潜在治疗作用.
- 针对IBS的向微生物群疗法进行进一步的研究,这些微生物签名的信息为个性化治疗策略提供了理由.
相关概念视频
01:17Irritable Bowel Syndrome I: Introduction
203
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
203
01:30Irritable Bowel Syndrome III: Medical and Nursing Management
117
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
117
01:30Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
96
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
96
01:17Chronic Bowel Disorders: Introduction
310
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
310
01:17Drugs for Treatment of Diarrhea-Predominant IBS
117
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
117
01:21Drugs for Treatment of Constipation-Predominant IBS
109
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
109